XML 25 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Marketable Equity Securities
 12 Months Ended
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE EQUITY SECURITIES
NOTE 3:- MARKETABLE EQUITY SECURITIES

 

  a. The Company owned 52,249 ordinary shares of Can-Fite representing approximately 0.04% of Can-Fite’s issued and outstanding share capital as of December 31, 2019. As of December 31, 2019, the investment amounted to $6. During the year ended December 31, 2019 the Company recorded a loss of $26. During 2020 the Company sold all of its Can-Fite ordinary shares for net proceeds of approximately $3.

 

  b. As of December 31, 2019 the Company held 25,000 ordinary shares of Cannabics Pharmaceuticals, Inc. (“Cannabics”) representing less than 1% of its issued and outstanding share capital as of that day. As of December 31, 2019, the investment amounted to $3. During 2020 the Company sold all of its Cannabics ordinary shares for net proceeds of approximately $260.

 

    During the fourth quarter of 2019, the Company sold 2,238,944 shares of Cannabics through a broker at the amount of $260 (see also Note 4) which were received as of the date of Financial Statements. The Company made a payment of $1 to the broker as a deposit for the Broker’s activity. During 2019 the Company recorded a loss of $501.

 

  c. The Company owns 18,822,533 ordinary shares of Bonus representing approximately 1.9% of Bonus’s issued and outstanding share capital as of December 31, 2020. As of December 31, 2020, the fair value of the investment, based on the quoted market price on TASE, amounts to $2,834 and is presented as Marketable equity securities in the accompanying consolidated balance sheet. During 2020 the Company recorded an income from sale of shares and revaluation of $1,197 with respect to this investment, see also Note 10.